Response to comment on: Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020)

Respir Med. 2022 Jan:191:106106. doi: 10.1016/j.rmed.2020.106106. Epub 2020 Aug 5.

Authors

Affiliations

¹ Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: eric.bateman@uct.ac.za.
² Sanofi, Chilly-Mazarin, France.
³ Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
⁴ Sanofi, Bridgewater, NJ, USA.
⁵ Evidera, St-Laurent, Quebec, Canada.
⁶ Oxford Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

PMID: 32839071
DOI: 10.1016/j.rmed.2020.106106

No abstract available

Keywords: Dupilumab; Indirect treatment comparison; Maintenance OCS; Mepolizumab; Severe eosinophilic asthma.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Asthma* / drug therapy
Biological Products* / therapeutic use
Humans

Substances

Antibodies, Monoclonal, Humanized
Biological Products
dupilumab